Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
A phase 3 trial of 177Lu-TLX250 in renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
Overview
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC is a phase 3 interventional study registered as NCT07197580 by Telix Pharmaceuticals (Innovations) Pty Limited, with 40 participants planned, started 2026-03-25 and due to reach its primary completion in 2027-08-31. Interventions recorded: 177Lu-TLX250.
Similar pages
not linked directly; found by shared links- TrialThe OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Shares Medpace and the tag pipeline.
- TrialAzeliragon in MGMT Unmethylated Glioblastoma
Shares Medpace and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Medpace and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Medpace and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Medpace and the tag pipeline.
- Trial[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Medpace and the tag pipeline.
- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Renal cell carcinoma and the tag pipeline.